BI-3663 is primarily investigated for its potential in cancer therapy, particularly as an inhibitor targeting specific proteins involved in tumor growth and survival. It shows promise in disrupting pathways that contribute to the proliferation of cancer cells, making it a candidate for treating certain types of cancers, such as hematologic malignancies or solid tumors. Researchers are exploring its efficacy in preclinical studies to determine its ability to enhance the effectiveness of existing treatments or as a standalone therapeutic agent. Its application could potentially lead to the development of targeted therapies with fewer side effects compared to traditional chemotherapy.